Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies
The latest clinical and real-world evidence of chimeric antigen receptor (CAR) T-cell therapy continues to challenge standard treatment paradigms for many hematologic malignancies with limited treatment options. In particular, recently approved CAR T-cell therapies are forging a path towards improvi...
Saved in:
| Main Authors: | Raphaël Stadelmann, Anne Cairoli, Caroline Arber |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2022-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2022.13.085 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CAR-T Therapy Beyond B-Cell Hematological Malignancies
by: Martina Canichella, et al.
Published: (2025-01-01) -
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
by: Zhongfei Tao, et al.
Published: (2024-12-01) -
Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignancies
by: Andres E. Daryanani, et al.
Published: (2024-12-01) -
PET/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies
by: Shashi B. Singh MBBS, et al.
Published: (2024-05-01) -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES
by: Ugo Testa, et al.
Published: (2024-02-01)